Nick Plumeridge is a seasoned life science executive with over 30 years of global pharmaceutical experience in Europe, North America, and Asia Pacific and Emerging Markets. He has held senior roles in corporate development, strategic planning, and commercial operations. Throughout his career, Nick has worked with multinational corporations such as Aventis, Serono, Takeda, Quntiles Transnational as well as early-stage start-ups including Epirus and Mabxience. Nick’s expertise spans the entire product lifecycle from early product development through to commercial launch of new chemical entities (NCEs), biologics, and biosimilars.

Nick’s international career has taken him to Tokyo, Sydney, Manila, Zug, London, and Madrid. He also has extensive corporate experience working in the U.S., China, Korea, Latin America, and the MENA region. Nick has a strong track record in corporate business development including M&A, in- and out- licensing of early and late-phase assets, and executing transformational deals. He has led major transactions ranging from multimillion-dollar M&As, such as Nycomed, Valeant, and Fresenius Kabi, to acquisitions, joint ventures, and licensing of deals for biologics, small molecules, cell lines, and development portfolios.

Nick also has experience in fundraising, working with private equity and venture capital from start-up to IPO, notably with Mabxience, Epirus, and Invida. Currently, Nick is engaged as an independent consultant focused on developing Mabloc’s early-stage strategies, partnerships, and alliances.